GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Short Percentage of Float

Biomarin Pharmaceutical (FRA:BM8) Short Percentage of Float


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Biomarin Pharmaceutical's Short Percentage of Float

For the Biotechnology subindustry, Biomarin Pharmaceutical's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Short Percentage of Float falls into.


;
;

Biomarin Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Short Percentage of Float
Comparable Companies
INSM INCY MRNA RPRX EXEL ASND TECH ROIV CORT HALO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
https://www.biomarin.com
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines